TABLE 3.

Clinical and in vitro resistance: caspofungin in candidiasis patientsb

Species (reference)Infection typeAntifungal treatmentaAgents (MICs in μg/ml)Comment(s)
C. glabrata (28)CandidemiaCSFCSF (2), ANF (0.5), MCF (0.25)Mutation in FKS2, F659V
C. albicans (2)EsophagitisFLC, VRC, CSF, AMBCSF (2), MCF (1)Mutation in FKS1, F641S
C. tropicalis (6)CandidemiaCSF, VRCCSF (4), ANF (2), MCF (2)Mutation, 50× increase in IC50
C. tropicalis (6)CandidemiaCSF, AMBCSF (4), ANF (1), MCF (2)Mutation, 50× increase in IC50
C. tropicalis (6)CandidemiaCSF, FLCCSF (1), ANF (0.5), MCF (0.5)Mutation, 38× increase in IC50
C. albicans (14)EsophagitisCSF, AMB, FLC, VRC, ITZ, MCFCSF (2), ANF (1), MCF (2)Mutations, S645F and R1361H
  • a Antifungal agents administered to patient.

  • b AMB, amphotericin B; ANF, anidulafungin; CSF, caspofungin; FLC, fluconazole; ITZ, itraconazole; MCF, micafungin; VRC, voriconazole; IC50, concentration that inhibits 50% of enzyme activity.